Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2007-09-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0708275PMID 17900102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct cellular responses to platinum-induced DNA damage.

  2007cited by this paper
• Satraplatin: an orally available platinum analog for the treatment of cancer

  2006cited by this paper
• The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes.

  2006cited by this paper
• Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake.

  2005cited by this paper
• Influence of the π–π interaction on the hydrogen bonding capacity of stacked DNA/RNA bases

  2005cited by this paper
• Cisplatin carbonato complexes. Implications for uptake, antitumor properties, and toxicity.

  2005cited by this paper
• Hydrogen bonding and covalent effects in binding of cisplatin to purine bases: ab initio and atoms in molecules studies.

  2005cited by this paper
• Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids.

  2004cited by this paper
• The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines.

  2004cited by this paper
• Platinums: Extending Their Therapeutic Spectrum

  2004cited by this paper
• New Molecular Descriptors Based on Local Properties at the Molecular Surface and a Boiling-Point Model Derived from Them

  2004cited by this paper
• Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS).

  2004cited by this paper
• Local molecular properties and their use in predicting reactivity

  2003cited by this paper
• (Aminoethanol)dichloroplatinum(II) complexes: influence of the hydroxyethyl moiety on 5'-GMP and DNA binding, intramolecular stability, the partition coefficient and anticancer activity.

  2002cited by this paper
• Calculation of the hydrophobicity of platinum drugs.

  2001cited by this paper
• Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes.

  2000cited by this paper
• Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

  2000cited by this paper
• In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands.

  1999cited by this paper
• Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.

  1994cited by this paper
• In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

  1993cited by this paper
• Cellular accumulation of the anticancer agent cisplatin: a review.

  1993cited by this paper
• Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

  1992cited by this paper
• Hydrophobicity parameters for platinum complexes.

  1991cited by this paper
• Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design.

  1987cited by this paper
• Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships.

  1986cited by this paper
• Structure and activity relationships of platinum complexes with anti-tumour activity.

  1975cited by this paper

• A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis.

  2025cites this paper
• Limantrafin-BODIPY Conjugates Reduce Stemness and Metastatic Potential via Superoxide Driven Phototherapy in Triple Negative Breast Cancer.

  2025cites this paper
• Lipophilic integrated bioorthogonal self-catalyzed nitric oxide donor-platinum(IV) prodrugs for enhanced antitumor efficacy against esophageal cancer.

  2025cites this paper
• Potent anticancer 5-fluorouracil platinum(IV) prodrugs.

  2025cites this paper
• Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway.

  2024cites this paper
• Fluorescence‐Guided Spatial Drug Screening in 3D Colorectal Cancer Spheroids

  2024cites this paper
• 1,3,5-Triaza-7-phosphaadamantane and Cyclohexyl Groups Impart to Di-Iron(I) Complex Aqueous Solubility and Stability, and Prominent Anticancer Activity in Cellular and Animal Models.

  2024cites this paper
• Targeting Ribosome Biogenesis for Cancer Therapy with Oral Platinum Complexes

  2024cites this paper
• Anion-selective "Turn-on" two color phosphorescent probes based on "Pd-Pd" interaction of a series of cyclometallated Palladium (II) complexes induced by a self-assembly in aqueous solution.

  2023cites this paper
• Synthesis, crystal structure, cytotoxicity, in-detail experimental and computational CT-DNA interaction studies of 2-picolinate Pd(II) and Pt(II) complexes

  2023cites this paper
• Cytotoxic potential of silver, palladium, rhodium, ruthenium, and iridium complexes of a cycloheptyl-substituted lipophilic N-heterocyclic carbene ligand

  2023cites this paper
• Beyond the TPP+ “gold standard”: a new generation mitochondrial delivery vector based on extended PN frameworks

  2023cites this paper
• Impact of Hydrophobic Chains in Five-Coordinate Glucoconjugate Pt(II) Anticancer Agents

  2023cites this paper
• Exploring the antioxidant, antimicrobial, cytotoxic and biothermodynamic properties of novel morpholine derivative bioactive Mn(ii), Co(ii) and Ni(ii) complexes – combined experimental and theoretical measurements towards DNA/BSA/SARS-CoV-2 3CLPro

  2023cites this paper
• Hydration patterns of rings in drugs and relationship to lipophilicity: A DFT study

  2022cites this paper
• Application of cyclometalated rhodium(III) complexes as therapeutic agents in biomedical and luminescent cellular imaging

  2022cites this paper
• Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells

  2022cites this paper
• Synthesis and Antitumor Activity of a GSH Inert Bisphosphonate Platinum (II) Complex

  2022cites this paper
• NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents.

  2022cites this paper
• QSPR study on Hydrophobicity of Pt(II) complexes with surface electrostatic potential-based descriptors.

  2022cites this paper
• In-vitro anticancer profile of recent ruthenium complexes against liver cancer

  2022cites this paper
• Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity

  2022cites this paper
• Can the Self-Assembling of Dicarboxylate Pt(IV) Prodrugs Influence Their Cell Uptake?

  2021cites this paper
• Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response.

  2021cites this paper
• Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.

  2021cites this paper
• Platinum(iv)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light†

  2021cites this paper
• High-Valent Platinum Complexes

  2021cites this paper
• Pt(IV) Prodrugs with NSAIDs as Axial Ligands

  2021cites this paper
• Copper(II) Pyridyl Amino-Phenolates: Hypoxia-Selective, Nucleus Targeting Cytotoxins, and Magnetic Resonance Probes.

  2021cites this paper
• Prediction of the hydrophobicity of platinum(IV) complexes based on molecular surface properties.

  2021cites this paper
• Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents

  2020cites this paper
• An anthracene-pendant ruthenium(ii) complex conjugated to a biotin anchor, an essential handle for photo-induced anti-cancer activity

  2020cites this paper
• Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase.

  2019cites this paper
• A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.

  2019cites this paper
• An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.

  2019cites this paper
• Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.

  2019cites this paper
• The interaction of silver(II) complexes with biological macromolecules and antioxidants

  2019cites this paper
• Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity.

  2019cites this paper
• Biological activity and photocatalytic properties of a naphthyl-imidazo phenanthroline (HNAIP) ligand and its [Ir(ppy)2(HNAIP)]Cl and [Rh(ppy)2(HNAIP)]Cl complexes.

  2019cites this paper
• A Potential Bone-Targeting Hypotoxic Platinum(II) Complex with an Unusual Cytostatic Mechanism toward Osteosarcoma Cells.

  2018cites this paper
• Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery.

  2018cites this paper
• Synthesis, structures and anticancer potentials of platinum(II) saccharinate complexes of tertiary phosphines with phenyl and cyclohexyl groups targeting mitochondria and DNA.

  2018cites this paper
• Development and Validation of Liquid Chromatography-Based Methods to Assess the Lipophilicity of Cytotoxic Platinum(IV) Complexes

  2018cites this paper
• A comparative study on in vitro cytotoxicity, cellular uptake, localization and apoptosis-inducing mechanism of two ruthenium(II) complexes

  2018cites this paper
• Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

  2018cites this paper
• Synthesis and biological evaluation of substituted 3-(2'-benzimidazolyl)coumarin platinum(II) complexes as new telomerase inhibitors.

  2018cites this paper
• An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties.

  2017cites this paper
• Dinuclear Platinum(II) Complexes with Bone-Targeting Groups as Potential Anti-Osteosarcoma Agents.

  2017cites this paper
• Anticancer Activity of Iridium(III) Complexes Based on a Pyrazole-Appended Quinoline-Based BODIPY.

  2017cites this paper
• Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents.

  2017cites this paper
• Coordination-Driven Self-Assembly of Ionic Irregular Hexagonal Metallamacrocycles via an Organometallic Clip and Their Cytotoxicity Potency.

  2017cites this paper
• Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure–Activity Relationship and Application as Orally Available Prodrugs

  2017cites this paper
• Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes.

  2017cites this paper
• In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety.

  2017cites this paper
• Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.

  2017cites this paper
• Triphenylstannyl((arylimino)methyl)benzoates with selective potency that induce G1 and G2/M cell cycle arrest and trigger apoptosis via ROS in human cervical cancer cells.

  2017cites this paper
• Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.

  2017cites this paper
• Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d

  2016cites this paper
• Using DFT methodology for more reliable predictive models: Design of inhibitors of Golgi α-Mannosidase II.

  2016cites this paper
• Ferrocenyl-Coupled N-Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs.

  2016cites this paper
• Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches.

  2016cites this paper
• Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.

  2016cites this paper
• The studies on the cytotoxicity in vitro, cellular uptake, cell cycle arrest and apoptosis-inducing properties of ruthenium methylimidazole complex [Ru(MeIm)4(p-cpip)](2.).

  2016cites this paper
• New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.

  2015cites this paper
• Redox-active and DNA-binding coordination complexes of clotrimazole.

  2015cites this paper
• Highly positive-charged zinc(II) phthalocyanine as non-aggregated and efficient antifungal photosensitizer.

  2015cites this paper
• Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain.

  2015cites this paper
• Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance

  2015cites this paper
• Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.

  2014cites this paper
• Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand.

  2014cites this paper
• Luminescent oligo(ethylene glycol)-functionalized cyclometalated platinum(II) complexes: cellular characterization and mitochondria-specific localization.

  2014cites this paper
• Platinum‐Based Anticancer Agents

  2014cites this paper
• Cellular Accumulation, Lipophilicity and Photocytotoxicity of Diazido Platinum(IV) Anticancer Complexes

  2014cites this paper
• Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth.

  2014cites this paper
• Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.

  2014cites this paper
• Phosphorescent cellular probes and uptake indicators derived from cyclometalated iridium(III) bipyridine complexes appended with a glucose or galactose entity.

  2013cites this paper
• Synthesis of [PtCl2(4,4'-dialkoxy-2,2'-bipyridine)] complexes and their in vitro anticancer properties.

  2013cites this paper
• Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes.

  2013cites this paper
• Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.

  2012cites this paper
• Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.

  2012cites this paper
• Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.

  2012cites this paper
• Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues

  2012cites this paper
• Synthesis, Emission Characteristics, Cellular Studies, and Bioconjugation Properties of Luminescent Rhenium(I) Polypyridine Complexes with a Fluorous Pendant

  2012cites this paper
• Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes

  2011cites this paper
• Chemistry and Biological Activity of Platinum Amidine Complexes

  2011cites this paper
• Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?

  2011cites this paper
• Luminescent rhenium(I) polypyridine complexes appended with an α-D-glucose moiety as novel biomolecular and cellular probes.

  2011cites this paper
• Organometallic half-sandwich iridium anticancer complexes.

  2011cites this paper
• Structure, photophysical and electrochemical properties, biomolecular interactions, and intracellular uptake of luminescent cyclometalated iridium(III) dipyridoquinoxaline complexes.

  2010cites this paper
• Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells.

  2010cites this paper
• Platinum Complexes as Anti‐Cancer Drugs: Modeling of Structure, Activation and Function

  2010cites this paper
• Density Functional Theory Characterization and Descriptive Analysis of Cisplatin and Related Compounds

  2009cites this paper
• QM/MM investigation into binding of square-planar platinum complexes to DNA fragments

  2009cites this paper
• Density functional theory for transition metals and transition metal chemistry.

  2009cites this paper
• Platinum drug distribution in cancer cells and tumors.

  2009cites this paper